Particle.news
Download on the App Store
12 ARTICLES
·
4w ago

Ivonescimab Extends Survival in China Phase 3 Trial for Squamous Lung Cancer

The China-only study reported a statistically significant overall survival gain but also higher rates of bleeding and serious adverse events, leaving regulators and investors to await global trial data to judge wider use.

**SINGLE USE** Radial lung cancer scan. Cancerous tumour consisting of a group of cancerous cells that invade nearby tissues and destroy them, they can also spread in metastases.
Image
Image
Clinical Trials Arena gives you the lung cancer highlights thus far from ASCO 2026. Credit: Keronn art / Shutterstock.com.

Overview

  • On Sunday, May 31, a phase 3 trial in China reported that ivonescimab plus chemotherapy reduced the risk of death by about 34 percent versus a PD‑1 immunotherapy plus chemotherapy.
  • Median overall survival was 27.9 months with ivonescimab compared with 23.7 months for the comparator, an increase of roughly four months and about a 15 percent improvement in median survival.
  • Safety data showed more bleeding and a higher rate of serious adverse events in the ivonescimab arm, with about one-quarter of patients experiencing some bleeding and roughly double the bleeding rate of the control group.
  • Summit holds commercialization rights outside China under a multibillion-dollar deal with Akeso, but regulators including the FDA are unlikely to accept China-only data and will look to ongoing global trials for approval decisions.
  • The readout strengthens commercial and scientific interest in PD‑1/VEGF bispecific antibodies but the field will watch interim results from the global Harmoni‑3 study later in 2026 to test whether the benefit and safety profile generalize beyond Chinese patients.